The unique history of Wilson Sonsini Goodrich & Rosati closely traces the birth and evolution of Silicon Valley.
For more than 60 years, Wilson Sonsini has represented technology pioneers associated with virtually every milestone innovation, as well as life sciences trailblazers shaping the future of healthcare.
Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.
Careers
We look for the best and brightest of tomorrow and develop careers from the ground up.
News and Featured Insights
Leading Matters
Client Highlights
Wilson Sonsini Advises Copart on Acquisition of ACV
On September 10, 2026, Copart, Inc., a global leader in online vehicle auctions, and ACV, a leading digital automotive marketplace and data services partner for dealers and commercial clients, announced a definitive agreement in which Copart will acquire all outstanding shares of ACV common stock, valued at approximately $1.9 billion. Wilson Sonsini Goodrich & Rosati advised Copart on the transaction.
Client Highlights
Wilson Sonsini Advises Fab2, Inc. on $500 Million Series A Financing at $3.7 Billion Valuation
On September 9, 2026, Fab2, Inc. (f/k/a Atomic Semi, Inc.) a semiconductor start-up that builds and mass-produces small chip fabs, announced the closing of a $500 million Series A financing led by Fundomo at a $3.7 billion valuation. Corner Capital, Paradigm, Duquesne Family Office, Maverick Silicon, StepStone Group, Protagonist, UDC Ventures, and angel investor Naval Ravikant also joined. Wilson Sonsini Goodrich & Rosati advised Fab2 on the transaction.
Client Highlights
Wilson Sonsini Advises Autodesk on $1 Billion Senior Notes Offering
On September 10, 2026, Autodesk, Inc., completed its offering of $500 million aggregate principal amount of 5.050 percent senior notes due 2029 and $500 million aggregate principal amount of 5.650 percent senior notes due 2033 (together, the “Notes”). Autodesk intends to use the net proceeds from the sale of the Notes, together with cash on hand, to repay $1 billion aggregate principal amount under its existing term loan credit agreement. Wilson Sonsini Goodrich & Rosati advised Autodesk on the transaction.
Client Highlights
Wilson Sonsini Advises Kura Oncology on Patent Matters Related to Launch of Caspian Therapeutics
On September 9, 2026, Kura Oncology (Kura), a biopharmaceutical company focused on precision medicines for the treatment of cancer, announced the launch of Caspian Therapeutics, a separately financed company established to advance small-molecule menin inhibitors for diabetes and cardiometabolic diseases. Caspian was established around KO-7246, a next-generation, highly selective menin inhibitor purpose-designed for chronic metabolic diseases, together with related intellectual property and know-how contributed by Kura. Kura will retain approximately half ownership of Caspian and board representation. Caspian will operate with dedicated leadership and external capital with access to Kura’s research, development, and corporate capabilities under an intercompany services arrangement. Wilson Sonsini Goodrich & Rosati advised Kura on patent matters related to the transaction.
Client Highlights
Wilson Sonsini Advises Latitude on $35 Million Series A
On September 9, 2026, Latitude, a global payments infrastructure company simplifying cross-border money movement, announced a $35 million Series A led by Oak HC/FT, with participation from NEA, Coinbase Ventures, Lightspeed Faction, and OpenFX. The round follows Latitude’s $8 million seed earlier this year and brings the company’s total funding to $43 million. Wilson Sonsini Goodrich & Rosati advised Latitude on the transaction.
Client Highlights
Wilson Sonsini Advises Poseidon Aerospace on $60 Million Series A
On September 8, 2026, Poseidon Aerospace, a start-up focused on developing and operating unmanned cargo aircraft, announced the close of an oversubscribed $60 million Series A financing. The round was led by TQ Ventures, with participation from JAWS, G Squared, Hanwha Asset Management USA, Starship Ventures, Drover Ventures, Draper Associates, and other investors. Wilson Sonsini Goodrich & Rosati advised Poseidon Aerospace on the transaction.
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025.